Rational use of eculizumab in secondary atypical hemolytic uremic syndrome.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
    • Publication Information:
      Original Publication: [Lausanne : Frontiers Research Foundation]
    • Subject Terms:
      Atypical Hemolytic Uremic Syndrome*/drug therapy; Humans ; Retrospective Studies ; Kidney ; Antibodies, Monoclonal, Humanized/therapeutic use ; Complement System Proteins/therapeutic use
    • Abstract:
      Background: Secondary atypical hemolytic uremic syndrome (secondary aHUS) is a heterogeneous group of thrombotic microangiopathies (TMA) associated with various underlying conditions. Unlike primary aHUS, there is still no hard evidence on the efficacy of complement blockade in secondary aHUS, since the two main series that investigated this subject showed discrepant results. Our work aims to reassess the efficacy of eculizumab in treating secondary aHUS.
      Methods: Observational, retrospective, single-center study, in which we analyzed the hematological and renal evolution of 23 patients diagnosed with secondary aHUS who received treatment with eculizumab and compared them with a control cohort of 14 patients. Complete renal response was defined as the recovery of renal function before the event, partial renal response as a recovery of 50% of lost glomerular filtration rate, and hematological response as normalization of hemoglobin and platelets.
      Results: We found no statistically significant differences in baseline characteristics or disease severity between both groups. After a median of 5 doses of eculizumab, the group of patients who received complement blockade presented a significant difference in renal response (complete in 52.3% of patients and partial in 23.8%) compared to the control cohort (complete response 14.3% and partial of 14.3%). Rates of hematological remission were similar in both groups (90.9% in the eculizumab cohort and 85.7% in the control cohort).
      Conclusion: Early and short-term use of eculizumab in patients with secondary aHUS could be an effective and safe therapeutic option, assuring better renal recovery compared to patients who do not receive complement blockade.
      Competing Interests: EM has received honoraria’s as speaker in conferences sponsored by AZ ALEXION, CSL VIFOR, OTSUKA and GSK. EG has received honoraria’s as speaker in conferences sponsored by AZ ALEXION. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
      (Copyright © 2024 Cordero, Cavero, Gutiérrez, Trujillo, Sandino, Auñón, Rivero and Morales.)
    • References:
      J Intensive Care. 2014 Dec 31;2(1):65. (PMID: 25705421)
      Clin J Am Soc Nephrol. 2019 Dec 6;14(12):1719-1732. (PMID: 31694864)
      Semin Arthritis Rheum. 2019 Aug;49(1):74-83. (PMID: 30598332)
      Nat Rev Nephrol. 2012 Nov;8(11):622-33. (PMID: 22986360)
      Blood. 2023 Mar 2;141(9):984-995. (PMID: 36322940)
      Clin J Am Soc Nephrol. 2010 Oct;5(10):1844-59. (PMID: 20595690)
      Nephrol Dial Transplant. 2017 Mar 1;32(3):466-474. (PMID: 28339660)
      Hypertension. 2020 Jun;75(6):1334-1357. (PMID: 32370572)
      Br J Haematol. 2013 Dec 4;:. (PMID: 24666021)
      Am J Kidney Dis. 2015 Jan;65(1):127-30. (PMID: 25446020)
      Clin Kidney J. 2013 Oct;6(5):484-5. (PMID: 26120441)
      Pediatr Nephrol. 2009 Apr;24(4):687-96. (PMID: 18800230)
      N Engl J Med. 2009 Oct 22;361(17):1676-87. (PMID: 19846853)
      Transplantation. 2015 Sep;99(9):1953-9. (PMID: 25651309)
      Nefrologia. 2017 Sep - Oct;37(5):478-491. (PMID: 28946961)
      Semin Thromb Hemost. 2010 Sep;36(6):673-81. (PMID: 20865645)
      Br J Haematol. 2010 Jan;148(1):37-47. (PMID: 19821824)
      Am J Transplant. 2013 Aug;13(8):2179-85. (PMID: 23763583)
      Front Immunol. 2022 Mar 22;13:845953. (PMID: 35392081)
      Kidney Int. 2017 Mar;91(3):539-551. (PMID: 27989322)
      Kidney Int Rep. 2021 Jan;6(1):11-23. (PMID: 33102952)
      Clin J Am Soc Nephrol. 2023 Jul 1;18(7):881-891. (PMID: 37094330)
      Kidney Res Clin Pract. 2022 Jul;41(4):412-421. (PMID: 35354244)
      Nat Rev Nephrol. 2012 Nov;8(11):643-57. (PMID: 23026949)
      Kidney Int. 2015 May;87(5):1061-73. (PMID: 25651368)
      Kidney Int. 2021 Jul;100(1):225-237. (PMID: 33307104)
      Nat Rev Nephrol. 2021 Aug;17(8):543-553. (PMID: 33953366)
      Blood. 2021 May 6;137(18):2419-2420. (PMID: 33956069)
      Kidney Int. 2020 Jun;97(6):1287-1296. (PMID: 32299680)
      N Engl J Med. 2013 Jun 6;368(23):2169-81. (PMID: 23738544)
      Kidney Int Rep. 2021 Feb 03;6(4):1099-1109. (PMID: 33912760)
      N Engl J Med. 2021 May 20;384(20):1931-1941. (PMID: 34010532)
      Kidney Int. 2019 Jun;95(6):1298-1300. (PMID: 31122707)
      Kidney Int. 2019 Jun;95(6):1443-1452. (PMID: 30982675)
    • Contributed Indexing:
      Keywords: atypical hemolytic uremic syndrome; complement; eculizumab; hemolysis; renal
    • Accession Number:
      A3ULP0F556 (eculizumab)
      0 (Antibodies, Monoclonal, Humanized)
      9007-36-7 (Complement System Proteins)
    • Publication Date:
      Date Created: 20240126 Date Completed: 20240129 Latest Revision: 20241023
    • Publication Date:
      20241023
    • Accession Number:
      PMC10808527
    • Accession Number:
      10.3389/fimmu.2023.1310469
    • Accession Number:
      38274833